The exponential growth of neurostimulation therapies has transformed management of treatment-resistant neurological and pain disorders. Deep brain stimulation (DBS), now standard-of-care for advanced Parkinson’s disease, essential tremor, and dystonia, has expanded to novel indications including treatment-resistant depression and obsessive-compulsive disorder (1, 2). The global DBS market reached USD 1.40 billion in 2024, with projections of USD 2.50 billion by 2030 (3). Similarly, spinal cord stimulation (SCS) has shown remarkable efficacy for complex regional pain syndrome and failed back surgery syndrome, with over 50,000 annual implantations globally (4, 5).

Despite technological advances, device-related infections remain a persistent challenge. A comprehensive meta-analysis analyzing 15,842 DBS procedures reported pooled infection rates of 5.0% (95% CI: 4.4–5.6%), with significant variation by indication: epilepsy (9.5%), dystonia (6.5%), and Parkinson’s disease (4.2%) (6). The JAMA Neurology INSITE registry documented SCS infection incidence of 2.8% (95% CI: 2.3–3.4%), with higher rates in revision procedures (4.1%) versus primary implantations (2.3%) (7).

Traditional analyses of medical device infections have focused on isolated domains—mechanistic studies, clinical trials, or policy evaluations. This fragmented approach fails to capture the complex interplay between biological, clinical, and systemic factors. We propose the Mechanism-Clinical-System (MCS) framework as an innovative analytical tool integrating these perspectives.

The Mechanism axis encompasses microbial pathogenesis, biofilm dynamics, sterilization technologies, and antimicrobial resistance. The Clinical axis addresses infection epidemiology, risk stratification, surgical techniques, and prophylactic protocols. The System axis examines regulatory frameworks, payment models, quality monitoring, and organizational culture.

China and the United States represent the world’s two largest healthcare markets with fundamentally different structures (8). The US performs approximately 12,000 DBS procedures annually across 150 centers, while China’s 200 + centers demonstrate greater volume heterogeneity (10–300 + cases/year) (9, 10). These structural differences create distinct infection control challenges and opportunities for bidirectional learning.

Contemporary neurostimulation systems share architectural features creating inherent sterilization challenges. DBS systems comprise intracranial electrodes (platinum-iridium contacts insulated with polyurethane or silicone), extension cables (40–60 cm), and implantable pulse generators (IPGs) in titanium enclosures (2, 11). The dominant manufacturers include Medtronic (Ireland/USA), Abbott (USA), and Boston Scientific (USA), which together account for >85% of the global market. In China, PINS Medical Technology (Beijing) and SceneRay (Suzhou) have emerged as domestic manufacturers with increasing market share (11). SCS systems introduce additional complexity through epidural lead designs with extensions measuring 25–100 cm (13).

The fundamental sterilization constraint derives from thermal sensitivity: internal electronics tolerate maximum 50–60 °C, while batteries risk thermal runaway above 65 °C (14). Steam autoclaving (121–134 °C) is therefore contraindicated. Polyurethane insulation undergoes hydrolytic degradation with repeated moisture-heat exposure (15).

Hardware infections demonstrate predictable anatomical patterns: IPG pocket (44%), lead/extension components (34%), with multi-site involvement in 22% (16). Staphylococcus epidermidis and S. aureus, implicated in >60% of infections, elaborate biofilm matrices conferring 100–1,000-fold increased antibiotic resistance—frequently necessitating hardware explantation (17, 18).

Ethylene oxide (EtO) remains predominant in US facilities, achieving microbicidal effects through irreversible alkylation (19). Cycles operate at 37–63 °C over 1–6 h, followed by 12–16 h aeration (20). EtO offers exceptional penetration but requires sophisticated ventilation for OSHA compliance and extended cycle times exceeding 12–18 h (21, 22).

Hydrogen peroxide (H₂O₂) plasma sterilization has achieved increasing prevalence in China. Systems employ H₂O₂ vapor at 37–50 °C with radiofrequency-generated plasma (11, 24). Cycles complete within 45–75 min with no environmental hazards (25). The principal limitation involves reduced penetration through extended lumens, though current-generation systems demonstrate improved capability (26, 27).

Clinical outcomes appear equivalent between modalities. US centers report DBS infection rates of 3.5–6.5% (28), comparable to European plasma-utilizing centers (3.8–6.2%) (29). Chinese facilities transitioning to plasma report reductions from 7–9% to 5–7% (30) (Figure 1).

Table 1 Comparison of ethylene oxide (EtO) and hydrogen peroxide plasma sterilization technologies for neurostimulation devices. Parameters include cycle time, temperature range, penetration capability, environmental considerations, and clinical infection outcomes.

Resistance profiles differ substantially between countries. MRSA prevalence averages 40–55% in the US versus 60–75% in China (31, 32), reflecting antibiotic consumption patterns: China’s per-capita use (~138 DDD/1000/day) exceeds the US (~13.6 DDD/1000/day) by 10-fold (33). Coagulase-negative staphylococci demonstrate methicillin resistance exceeding 70–85% in Chinese isolates versus 40–60% in the US (34).

These patterns directly influence prophylaxis strategies. US practice regarding routine MRSA prophylaxis remains controversial, while Chinese centers increasingly employ combination regimens despite limited supporting evidence (35, 36).

US standard practice employs weight-based cefazolin (2–3 g) administered 30–60 min pre-incision, limited to 24 h (37, 38). Chinese practice demonstrates greater heterogeneity: median prophylaxis of 5–7 days, with 30–40% of centers continuing 10–14 days (39, 40). Multiple factors drive extended prophylaxis: higher MRSA prevalence, medicolegal pressures, and longer operative times (4–6 h vs. 3–4 h) (41).

Evidence strongly supports short-duration protocols. Meta-analysis confirmed no benefit from prophylaxis exceeding 24 h (OR 0.98, 95% CI 0.63–1.52) while documenting increased resistance (42, 43). Chinese investigators reported infection reductions from 7.9 to 5.3% after shortening prophylaxis from 7 to 3 days (44).

Meta-analysis of 66 studies (12,258 patients) reported pooled DBS surgical site infection prevalence of 5.0% (95% CI: 4.0–6.0%), with considerable heterogeneity by indication (6). Infection timing demonstrates trimodal distribution: early (<30 days, 35%), intermediate (30–90 days, 40%), and late (>90 days, 25%) (16). Early infections typically reflect perioperative contamination, while late infections suggest hematogenous seeding or delayed-onset biofilm maturation (45).

Chinese registry data (1,250 procedures) reported 5.7% infection rate, with significant volume-outcome relationships: centers performing >50 annual procedures demonstrated 4.9% versus 7.3% in lower-volume facilities (10). Robot-assisted DBS procedures show promise for reducing operative time and potentially infection risk (41) (Figure 2).

Established risk factors include diabetes mellitus, immunosuppression, revision surgery, prolonged operative time, and previous surgical site infections (46, 47). Machine learning models incorporating preoperative variables demonstrate promising predictive accuracy (AUC 0.78–0.85) for identifying high-risk patients (48, 49).

Preventive interventions with strong evidence include chlorhexidine-alcohol skin preparation, antibiotic-impregnated envelopes for IPG placement, and standardized surgical bundles (50, 51). Novel approaches under investigation include antimicrobial coatings, bacteriophage therapy, and immunomodulation strategies (52, 53).

The US regulatory system operates through layered authorities. FDA mandates sterility assurance levels of 10⁻⁶, with facilities legally obligated to follow manufacturer Instructions for Use (21). CMS enforces infection control through Conditions of Participation affecting 40–60% of hospital revenue (54). The NHSN enables standardized surveillance across >6,800 facilities (55), while the Hospital-Acquired Condition Reduction Program penalizes worst-performing quartile institutions (56).

China’s NMPA provides primary regulatory authority, with recent reforms reducing Class III approval times from 3–4 years to 18–24 months (57, 58). The WS 310 standards specify CSSD requirements, though enforcement varies by facility tier (59). The China Hospital Infection Control Network encompasses approximately 2,500 hospitals (20% of eligible facilities), with surveillance remaining largely voluntary (60).

Table 2 Comparison of regulatory frameworks for neurostimulation device infection control between China and the United States. Categories include regulatory authority, sterility standards, surveillance systems, and quality incentive programs.

DBS implantation receives Medicare DRG reimbursement averaging $35,000–45,000, with surgical site infections generating $30,000–50,000 in uncompensated costs (54, 61). Value-based purchasing ties 3–4% of payments to quality metrics (62). Healthcare-associated infections cost the US healthcare system an estimated $28–45 billion annually (54).

China’s DRG-like systems (DIP) cover 80% of major-city admissions since 2017–2019 (63). Neurostimulation receives bundled payments of USD 11,000–17,000 (¥80,000–120,000), with infections not qualifying for additional payment (40). However, quality-based adjustments remain minimal (<1% vs. 3–4% in US) (56) (Table 3).

US CSSD technicians complete formal certification (400 h plus examination) with annual continuing education (59, 64). Chinese certification rates vary substantially: 68% in Beijing/Shanghai tier-3 hospitals versus 12% in tier-1 facilities (30, 60). US hospitals feature ≥1 infection preventionist per 100–150 beds versus 1 per 200–250 beds in China (44, 65). Leading Chinese centers feature world-class environments, though mid-tier hospitals rely on manual cleaning and paper-based tracking (60, 66).

The MCS framework reveals synergistic interactions across dimensions. Mechanism-level constraints (thermal sensitivity, biofilm dynamics) create universal challenges, while system factors determine technology choices. Antimicrobial resistance shaped by consumption policies necessitates different prophylaxis strategies. Clinical infection rates remain elevated despite decades of experience, with practice patterns reflecting system constraints including workforce gaps and economic pressures. Neither regulatory model optimally balances standardization, innovation, and equity.

US infection control evolved incrementally over 50 + years, creating embedded investment in specific technologies (67). China’s healthcare modernization compressed decades into 15–20 years, enabling technology leapfrogging but challenging infrastructure development (8). US per-capita health expenditure ($12,555) exceeds China’s ($936) by 13.4-fold, though Chinese hospitals benefit from bulk purchasing discounts and lower labor costs (8, 56).

Cultural factors influence implementation: US medical culture emphasizes litigation avoidance generating strong protocol adherence incentives, while Chinese operating rooms are evolving toward flat hierarchy models following WHO Surgical Safety Checklist adoption (59, 68).

US practices applicable to China: Expanding mandatory infection surveillance from 20% to ≥80% facility participation; increasing quality-based reimbursement adjustments from <1% to 3–5%; implementing nationally recognized professional certifications.

Chinese innovations applicable to US: Tiered implementation models accommodating facility heterogeneity; streamlined regulatory pathways accelerating innovation access; comprehensive digital health integration for workflow optimization (66, 69).

System-level implementation considerations: Successful adoption of these recommendations requires addressing several practical barriers. For surveillance system expansion in China, phased implementation beginning with provincial centers of excellence, supported by standardized electronic reporting templates and dedicated infection control personnel, could achieve 50% coverage within 3–5 years. Quality-based reimbursement adjustments necessitate development of validated, risk-adjusted outcome metrics that account for case complexity and patient comorbidities. Professional certification programs require investment in training infrastructure, examination development, and continuing education platforms. Cross-national knowledge transfer may be facilitated through joint professional society initiatives, international fellowship exchanges, and collaborative research networks building on existing relationships between academic medical centers (Figure 3).

This narrative review did not employ exhaustive search strategies or meta-analytic methods. Data quality varies substantially—US surveillance benefits from mature NHSN infrastructure while Chinese data derives from more limited networks. Specifically, Chinese infection surveillance data may underestimate true incidence due to voluntary reporting mechanisms, variable case definitions across institutions, and potential underreporting incentives within performance-based assessment systems. Additionally, published Chinese studies predominantly originate from tier-3 academic medical centers in major cities (Beijing, Shanghai, Guangzhou), limiting generalizability to the broader healthcare system including tier-1 and tier-2 facilities serving rural populations. Direct Sino-US comparisons derive from separate cohorts rather than designed comparative research. The MCS framework requires empirical validation; while the framework provides a useful conceptual structure for organizing complex multi-level factors, prospective studies are needed to determine whether MCS-guided interventions yield superior outcomes compared to conventional approaches. Future validation efforts should include multi-center trials testing framework-derived hypotheses and comparative effectiveness research across diverse healthcare settings.

Priority research includes comparative sterilization studies with clinical infection outcomes, pragmatic trials comparing prophylaxis duration, and machine learning-based risk prediction models (48, 70). System-level initiatives should prioritize international registries operated by professional societies, health economic modeling comparing regulatory approaches, and implementation science addressing the evidence-practice gap (71, 72).